Zogenix, Inc. (ZGNX) EPS Estimated At $-0.97; Nuveen Asset Management Lowered Nasdaq (NDAQ) Position

October 13, 2017 - By Adrian Mccoy

Nuveen Asset Management Llc decreased Nasdaq Inc (NDAQ) stake by 3.34% reported in 2017Q2 SEC filing. Nuveen Asset Management Llc sold 7,564 shares as Nasdaq Inc (NDAQ)’s stock declined 5.69%. The Nuveen Asset Management Llc holds 219,204 shares with $15.67 million value, down from 226,768 last quarter. Nasdaq Inc now has $12.40 billion valuation. The stock declined 0.77% or $0.58 reaching $74.33 per share. About 823,366 shares traded. Nasdaq Inc (NASDAQ:NDAQ) has risen 6.98% since October 13, 2016 and is uptrending. It has underperformed by 9.72% the S&P500.

Analysts expect Zogenix, Inc. (NASDAQ:ZGNX) to report $-0.97 EPS on November, 6.They anticipate $0.30 EPS change or 44.78% from last quarter’s $-0.67 EPS. After having $-0.90 EPS previously, Zogenix, Inc.’s analysts see 7.78% EPS growth. About 917,838 shares traded. Zogenix, Inc. (NASDAQ:ZGNX) has risen 52.57% since October 13, 2016 and is uptrending. It has outperformed by 35.87% the S&P500.

Among 6 analysts covering Zogenix (NASDAQ:ZGNX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zogenix had 14 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Zogenix, Inc. (NASDAQ:ZGNX) earned “Buy” rating by Stifel Nicolaus on Friday, September 29. Zacks upgraded Zogenix, Inc. (NASDAQ:ZGNX) rating on Saturday, August 15. Zacks has “Hold” rating and $22 target. Zacks upgraded Zogenix, Inc. (NASDAQ:ZGNX) on Thursday, August 6 to “Sell” rating. The stock has “Outperform” rating by Leerink Swann on Tuesday, August 11. The firm has “Buy” rating given on Friday, August 14 by Brean Capital. The stock of Zogenix, Inc. (NASDAQ:ZGNX) has “Buy” rating given on Friday, September 29 by William Blair. Stifel Nicolaus maintained Zogenix, Inc. (NASDAQ:ZGNX) rating on Monday, June 26. Stifel Nicolaus has “Buy” rating and $2600 target. Stifel Nicolaus maintained the shares of ZGNX in report on Thursday, September 21 with “Buy” rating. Brean Capital maintained Zogenix, Inc. (NASDAQ:ZGNX) on Thursday, September 17 with “Buy” rating. The rating was maintained by Leerink Swann on Monday, October 2 with “Outperform”.

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system therapies that address specific clinical needs for people living with orphan and other CNS disorders. The company has market cap of $1.21 billion. The Company’s primary area of therapeutic focus is epilepsy and related seizure disorders. It currently has negative earnings. The Company’s lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Analysts await Nasdaq Inc (NASDAQ:NDAQ) to report earnings on October, 25. They expect $1.02 EPS, up 12.09% or $0.11 from last year’s $0.91 per share. NDAQ’s profit will be $170.16 million for 18.22 P/E if the $1.02 EPS becomes a reality. After $1.02 actual EPS reported by Nasdaq Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Nuveen Asset Management Llc increased Calatlantic Group Inc stake by 154,471 shares to 601,763 valued at $2.23M in 2017Q2. It also upped Republic Svcs Inc (NYSE:RSG) stake by 81,386 shares and now owns 94,681 shares. Monster Beverage Corp New was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com